Covered recipient · General Payments record
DARYL SHERROD
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$4,550.51
- Reported across 270 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $345.05 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $56.16 | 3 |
| DEXCOM, INC. | $48.49 | 2 |
| Lilly USA, LLC | $41.33 | 2 |
| Novo Nordisk AS | $37.23 | 2 |
| Merck Sharp & Dohme Corporation | $35.33 | 2 |
| Acerta Pharma LLC | $31.73 | 1 |
| Amgen Inc. | $27.77 | 2 |
| Exact Sciences Corporation | $24.38 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $22.06 | 1 |
| GlaxoSmithKline, LLC. | $20.57 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $13.77 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117381560 | CMS |
| Amgen Inc. | $14.00 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117381562 | CMS |
| AstraZeneca Pharmaceuticals LP | $31.73 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105217273 | CMS |
| Boston Scientific Corporation | $22.06 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092391682 | CMS |
| Dexcom, Inc. | $24.38 | 05/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153294539 | CMS |
| Dexcom, Inc. | $24.11 | 07/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153294541 | CMS |
| Exact Sciences Corporation | $24.38 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114894716 | CMS |
| GlaxoSmithKline, LLC. | $20.57 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116070164 | CMS |
| Lilly USA, LLC | $21.60 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136117521 | CMS |
| Lilly USA, LLC | $19.73 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136117523 | CMS |
| Merck Sharp & Dohme LLC | $19.44 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141923711 | CMS |
| Merck Sharp & Dohme LLC | $15.89 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141957027 | CMS |
| Novo Nordisk Inc | $15.50 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097821250 | CMS |
| Novo Nordisk Inc | $21.73 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096867277 | CMS |
| PFIZER INC. | $17.76 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131696805 | CMS |
| PFIZER INC. | $19.96 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130879958 | CMS |
| PFIZER INC. | $18.44 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131252953 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.